Cart
sales@molnova.com
Erasin
CAS No. ——
Erasin( —— )
Catalog No. M17028 CAS No. ——
A potent, selective STAT3 inhibitor with IC50 of 9.7 uM, inhibits tyrosine phosphorylation of STAT3 with selectivity over STAT5 and STAT1 in cell-based assays.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameErasin
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective STAT3 inhibitor with IC50 of 9.7 uM, inhibits tyrosine phosphorylation of STAT3 with selectivity over STAT5 and STAT1 in cell-based assays.
-
DescriptionA potent, selective STAT3 inhibitor with IC50 of 9.7 uM, inhibits tyrosine phosphorylation of STAT3 with selectivity over STAT5 and STAT1 in cell-based assays; induces apoptosis in Erlotinib-resistant lung cancer cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight349.39
-
Molecular FormulaC20H19N3O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(N/N=C/C1=COC2=C(C=C(C(C)(C)C)C=C2)C1=O)C3=CN=CC=C3
-
Chemical Name(E)-N'-((6-(tert-butyl)-4-oxo-4H-chromen-3-yl)methylene)nicotinohydrazide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lis C, et al. Sci Rep. 2017 Dec 12;7(1):17390.
molnova catalog
related products
-
Quercetin pentaaceta...
Quercetin pentaacetate has diverse biological activities, including antioxidant, anti-inflammatory, and anticancer properties.
-
Napabucasin
Napabucasin (BBI-608) is a potent small-molecule inhibitor of STAT3 that has a broad spectrum of activity against stemness-high cancer cells (IC50=0.5-1.5 uM).
-
ML115
ML115 is a potent and selective activator of transcription 3 (STAT3), with abn EC50 of 2.0 nM, and is inactive against the related STAT1 and NFκB anti-targets.
